APPLE logo

Study timeline:       8/10/2023-7/31/2028
Investigators:         Barnhart, K; Schisterman, E
Funding:                  Eunice Kennedy Shriver National Institute of Child Health and Human Development

This is a parallel assignment, randomized, double blind clinical trial of double low-dose aspirin (162 mg/day) begun no later than 6 weeks 6 days gestation, through delivery, to investigate the effects of early initiation of prophylactic aspirin therapy compared to standard of care (placebo through 12 weeks’ gestation, 81 mg aspirin thereafter through delivery) on reducing risk of both pregnancy loss and preeclampsia in pregnant people with one or more risk factors.

ECHO Logo

Study timeline: 9/1/2023-5/31/2030
Funding: National Institutes of Health (NIH)
Investigator: Mumford, S

The ECHO Study is a National Institutes of Health (NIH) funded longitudinal study to seek the impact of broad range early environmental influences on child development and health.  In 2016, the NIH established the Environmental influences on Child Health Outcomes (ECHO) Program, an innovative and collaborative research initiative whose mission is to enhance the health of children for generations to come. The overarching scientific goal of ECHO is to advance understanding of the effects of a broad array of early environmental exposures on children’s development and health outcomes with high public health impact.

headshot

Kyle R. Jackson, MD, PhD

Kyle R. Jackson, MD PhD is an Assistant Professor of Surgery at the University of Pennsylvania and a Senior Scholar at the Center for Clinical Epidemiology and Biostatistics. He is a clinically active transplant surgeon with a clinical practice focused on adult and pediatric kidney transplantation, pancreas transplantation, and laparoscopic kidney donation. His primary research interest is in characterizing the impact of climate change and environmental pollutants on human health, with a particular focus on healthcare utilization and disease burden. His clinical practice has also led to a special interest in understanding how these environmental factors impact transplant patients, who are uniquely susceptible to these effects due to the profound immunomodulation necessary to facilitate successful transplantation as well as highly prevalent place-based vulnerabilities. He also uses national registry and claims-based datasets to solve clinically relevant problems in solid organ transplantation - such as identifying optimal transplant strategies for the immunologically high-risk, quantifying and improving equity and access to organ transplantation, and characterizing the clinical and financial impact of post-transplant complications. Dr. Jackson has received direct research support as a Principal Investigator from both foundational and federal sources, such as the NIH/NIDDK and the Doris Duke Foundation.

Veeva logo

Veeva Vault: an FDA 21 CFR Part 11 compliant clinical data management tool used to manage projects requiring FDA oversight, such as trials of an Investigational New Drug (IND) or New Drug Applications (NDA). 

Access to our current list of Veeva Vault projects.

logo for THRIVE

Funding: NIH/NIDDK
Investigator(s): Dember, LM; Flythe, JE; Crews, D

The focus of this study is on vascular access for hemodialysis. This is a randomized clinical trial testing 3 educational approaches to help patients with advanced chronic kidney disease prepare for placement of hemodialysis vascular access. Study participants will each be assigned to one of the 3 approaches...

logo for SMARRT-HD

Funding: PCORI
Co-Principal Investigator(s):  Flythe, JE; Dember, LM

The SMaRRT-HD Study, also known as “Comparative Effectiveness of Two Approaches to Symptom Monitoring in Hemodialysis” compares two approaches for monitoring and addressing symptoms among adult patients with kidney failure who are treated with hemodialysis.

logo for PRECINCT

Funding: NCI
Investigator(s): Mason, N; Long, Q

The mission of the Pre-medical Cancer Immunotherapy Network for Canine Trials (PRECINCT), supported by grants from the National Cancer Institute, is to provide infrastructure and oversight to a highly collaborative and interactive network of researchers and clinician scientists working to accelerate the application of next generation immunotherapies through comparative oncology. Pet dogs spontaneously develop cancers that share remarkable similarities in biology, genetics, treatment response and outcome to human patients. Evaluating next generation immunotherapies and combination immunotherapies in immune competent canine patients aims not only to provide more effective treatments for these pets but also unparalleled insight into response and response prediction through correlative biomarker discovery. This work will aid human clinical trial design and accelerate the translation of novel immunotherapies and immunotherapy protocols into the human clinic.

DIVA logo

Funding: NHLBI
Investigator: Foglia, E

The DIVA Trial is a National Heart, Lung and Blood Institute funded multicenter randomized comparative effectiveness trial comparing 2 FDA-approved modes of respiratory support to prevent extubation failure among extremely preterm infants. The preterm (23-28 weeks gestation) babies will be randomly placed into either a non-invasive neurally adjusted ventilatory assist or non-synchronized nasal intermittent positive pressure ventilation treatment for bronchopulmonary dysplasia.  Bronchopulmonary dysplasia is the most common complication for premature babies and is the leading respiratory cause of death.

Logo for EMO

Funding: NHLBI
Investigator(s): Bonafide, C

The EMO effectiveness deimplementation trial, funded by the National Heart, Lung, and Blood Institute is a four-phase project seeking to eliminate monitor over use in children with bronchiolitis and to identify a de-implementation strategy.  Bronchiolitis is the leading cause of infant hospitalization.  There are over 100,000 admissions and 1.7 billion dollars in hospital charges.  Pulse oximetry is a common intervention but does not improve outcomes for patients during hospitalization when supplemental oxygen is being administered.  This study discourages the continuous use of monitoring SPO2 for children who are in room air which will maximize quality and minimize waste in our health care. 

Subscribe to